Journal of neuro-oncology · 2025
Redefining the therapeutic landscape of glioblastomas and brain metastasis through cesium brachytherapy and low-kV intra-operative radiation therapy (IORT).
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chuck Carlin, Teshome Abigail, Lin Alice, Sayeed Sumaiya, Wang Elaina, Amaral-Nieves Natalie, Taman Mazen, Oldam Joseph, Chen Hsien-Chung, Desai Brijal, Kopecky Andrew, Rivard Mark J, Sarangi Sasmit, Elinzano Heinrich, Wong Eric T, Cifarelli Christopher P, Chen Clark C
Аннотация
BACKGROUND: The role of brachytherapy in neuro-oncology has evolved through periods of enthusiasm and skepticism.
OBJECTIVE: We examined the historical landscape of brachytherapy, tracing influential studies, clinical adoption patterns, technological advancements, and ongoing trials that reflect its resurgence in neuro-oncology.
METHODS: We conducted a scoping literature review of brachytherapy.
RESULTS: Because of their favorable safety profiles, cesium-131brachytherapy and low-kV intra-operative radiation therapy (IORT) have emerged as a preferred platform for intracranial brachytherapy. In glioblastoma and brain metastasis (BM) patients, published literature indicates that cesium-131 brachytherapy and low-kV IORT do not increase the risk of surgical morbidity or procedural complications. Radiation necrosis remains rare in most glioblastoma and brain metastasis cases. Consistent across the available literature, cesium-131 brachytherapy and low-kV IORT are associated with excellent local control, including large lesions with a maximal diameter of > 3.5 cm. Ongoing clinical trials aim to compare the effectiveness of these adjunctive radiation platforms to the current standard of care, while also exploring their potential for integration into multimodal treatment strategies.
CONCLUSION: As prospective clinical trials mature, cesium-131 brachytherapy and IORT are poised to redefine the therapeutic landscape for glioblastoma and brain metastasis management.
OBJECTIVE: We examined the historical landscape of brachytherapy, tracing influential studies, clinical adoption patterns, technological advancements, and ongoing trials that reflect its resurgence in neuro-oncology.
METHODS: We conducted a scoping literature review of brachytherapy.
RESULTS: Because of their favorable safety profiles, cesium-131brachytherapy and low-kV intra-operative radiation therapy (IORT) have emerged as a preferred platform for intracranial brachytherapy. In glioblastoma and brain metastasis (BM) patients, published literature indicates that cesium-131 brachytherapy and low-kV IORT do not increase the risk of surgical morbidity or procedural complications. Radiation necrosis remains rare in most glioblastoma and brain metastasis cases. Consistent across the available literature, cesium-131 brachytherapy and low-kV IORT are associated with excellent local control, including large lesions with a maximal diameter of > 3.5 cm. Ongoing clinical trials aim to compare the effectiveness of these adjunctive radiation platforms to the current standard of care, while also exploring their potential for integration into multimodal treatment strategies.
CONCLUSION: As prospective clinical trials mature, cesium-131 brachytherapy and IORT are poised to redefine the therapeutic landscape for glioblastoma and brain metastasis management.